DE69230882T2 - Cytosindeaminase negatives selektionssystem zur genübertragung und therapien - Google Patents

Cytosindeaminase negatives selektionssystem zur genübertragung und therapien

Info

Publication number
DE69230882T2
DE69230882T2 DE69230882T DE69230882T DE69230882T2 DE 69230882 T2 DE69230882 T2 DE 69230882T2 DE 69230882 T DE69230882 T DE 69230882T DE 69230882 T DE69230882 T DE 69230882T DE 69230882 T2 DE69230882 T2 DE 69230882T2
Authority
DE
Germany
Prior art keywords
therapies
cytosindeaminase
communication
selection system
negative selection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69230882T
Other languages
English (en)
Other versions
DE69230882D1 (de
Inventor
A Mullen
Michael Blaese
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Application granted granted Critical
Publication of DE69230882D1 publication Critical patent/DE69230882D1/de
Publication of DE69230882T2 publication Critical patent/DE69230882T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Brushes (AREA)
  • Exchange Systems With Centralized Control (AREA)
  • Devices For Checking Fares Or Tickets At Control Points (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DE69230882T 1991-07-03 1992-06-30 Cytosindeaminase negatives selektionssystem zur genübertragung und therapien Expired - Fee Related DE69230882T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/725,076 US5358866A (en) 1991-07-03 1991-07-03 Cytosine deaminase negative selection system for gene transfer techniques and therapies
PCT/US1992/005385 WO1993001281A1 (en) 1991-07-03 1992-06-30 Cytosine deaminase negative selection system for gene transfer techniques and therapies

Publications (2)

Publication Number Publication Date
DE69230882D1 DE69230882D1 (de) 2000-05-11
DE69230882T2 true DE69230882T2 (de) 2000-11-09

Family

ID=24913069

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69230882T Expired - Fee Related DE69230882T2 (de) 1991-07-03 1992-06-30 Cytosindeaminase negatives selektionssystem zur genübertragung und therapien

Country Status (12)

Country Link
US (2) US5358866A (de)
EP (1) EP0595873B1 (de)
JP (1) JP3386461B2 (de)
AT (1) ATE191505T1 (de)
AU (1) AU667820B2 (de)
CA (1) CA2112395C (de)
DE (1) DE69230882T2 (de)
DK (1) DK0595873T3 (de)
ES (1) ES2152929T3 (de)
GR (1) GR3033909T3 (de)
SG (1) SG52475A1 (de)
WO (1) WO1993001281A1 (de)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6337209B1 (en) 1992-02-26 2002-01-08 Glaxo Wellcome Inc. Molecular constructs containing a carcinoembryonic antigen regulatory sequence
CA2042093C (en) * 1990-05-09 2002-12-24 Gyula Hadlaczky Cell line carrying an excess of mammalian centromeres
US6555370B1 (en) * 1990-11-13 2003-04-29 Immunex Corporation Bifunctional selectable fusion genes
US5358866A (en) * 1991-07-03 1994-10-25 The United States Of America As Represented By The Department Of Health And Human Services Cytosine deaminase negative selection system for gene transfer techniques and therapies
WO1993010218A1 (en) * 1991-11-14 1993-05-27 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Vectors including foreign genes and negative selective markers
FR2683725B1 (fr) * 1991-11-15 1995-07-07 Pasteur Institut Composition cellulaire pour le traitement des organismes humains ou animaux.
CA2134763A1 (en) * 1992-05-01 1993-11-11 Kenneth W. Culver Bystander effect tumoricidal therapy
EP0804590A1 (de) * 1993-05-21 1997-11-05 Targeted Genetics Corporation Bifunktionelle selektierbare fusionsgene auf dem cytosin-deaminase (cd) gen beruhend
US6451571B1 (en) 1994-05-02 2002-09-17 University Of Washington Thymidine kinase mutants
CA2189543A1 (en) * 1994-05-02 1995-11-09 Lawrence A. Loeb Thymidine kinase mutants
JP4303315B2 (ja) 1994-05-09 2009-07-29 オックスフォード バイオメディカ（ユーケー）リミテッド 非交差性レトロウイルスベクター
US6013517A (en) 1994-05-09 2000-01-11 Chiron Corporation Crossless retroviral vectors
US5856153A (en) * 1994-11-17 1999-01-05 Cayla Suicide genes and new associations of pyrimidine nucleobase and nucleoside analogs with new suicide genes for gene therapy of acquired diseases
US6638762B1 (en) * 1994-11-28 2003-10-28 Genetic Therapy, Inc. Tissue-vectors specific replication and gene expression
US5998205A (en) 1994-11-28 1999-12-07 Genetic Therapy, Inc. Vectors for tissue-specific replication
US20020068049A1 (en) * 1998-09-10 2002-06-06 Henderson Daniel R. Tissue specific adenoviral vectors
WO1997015668A2 (en) * 1995-10-23 1997-05-01 Board Of Regents, The University Of Texas System Methods and compositions comprising glut-2 and glut-2 chimeras
WO1997029201A2 (de) * 1996-02-07 1997-08-14 Max-Delbrück-Centrum für Molekulare Medizin Retroviraler vektor für den gentransfer eines il6-antagonisten in humane hämatopoetische stammzellen
US20020160970A1 (en) * 1996-04-10 2002-10-31 Gyula Hadlaczky Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes
US6025155A (en) * 1996-04-10 2000-02-15 Chromos Molecular Systems, Inc. Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes
US20030033617A1 (en) * 1996-04-10 2003-02-13 Gyula Hadlaczky Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes
US6077697A (en) * 1996-04-10 2000-06-20 Chromos Molecular Systems, Inc. Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes
US6566089B1 (en) * 1996-09-04 2003-05-20 Tularik Inc. Cell-based drug screens for regulators of gene expression
US7018631B1 (en) 1998-02-19 2006-03-28 St. Jude Children's Research Hospital Compositions and methods for sensitizing and inhibiting growth of human tumor cells
GB9810752D0 (en) * 1998-05-19 1998-07-15 Glaxo Group Ltd Cystosine deaminase gene
US7186409B2 (en) 1998-08-14 2007-03-06 The Children's Medical Center Corporation Neural stem cells and use thereof for brain tumor therapy
US20020115213A1 (en) * 1998-08-14 2002-08-22 Northeastern Ohio Universities Of Medicine Engraftable neural progenitor & stem cells for brain tumor therapy
US5958767A (en) 1998-08-14 1999-09-28 The Children's Medical Center Corp. Engraftable human neural stem cells
FR2794025A1 (fr) * 1999-05-25 2000-12-01 Transgene Sa Composition destinee a la mise en oeuvre d'un traitement antitumoral ou antiviral chez un mammifere
US8716558B2 (en) 1999-06-30 2014-05-06 Marker Gene Technologies, Inc. Method of altering glycosylation of proteins in response to nojirimycin glucuronide in a plant cell expressing glucuronidase
US6656917B1 (en) * 1999-06-30 2003-12-02 Marker Gene Technologies, Inc. Compositions and methods for targeted enzymatic release of cell regulatory compounds
AU4744201A (en) * 2000-03-15 2001-09-24 Childrens Medical Center Systemic gene delivery vehicles for the treatment of tumors
US6579522B1 (en) 2000-06-27 2003-06-17 Genvec, Inc. Replication deficient adenoviral TNF vector
ATE510908T1 (de) * 2000-09-28 2011-06-15 Bioriginal Food & Science Corp Fad5-2, mitglied der desaturase-familie und verwendungen davon
EP1264891A1 (de) * 2001-05-31 2002-12-11 Plant Research International B.V. Veränderung des Pflanzen Genoms durch induzierbaren, ortsspezifischen Rekombination von Transgenen
JP2004536614A (ja) * 2001-08-01 2004-12-09 ユニバーシティ オブ ユタ Ｐｄｅ３環状ヌクレオチド・ホスホジエステラーゼのアイソフォーム選択的な阻害剤および活性化剤
US20030086903A1 (en) * 2001-11-02 2003-05-08 Genvec, Inc. Therapeutic regimen for treating cancer
EP1527183B1 (de) * 2002-07-26 2008-08-20 BASF Plant Science GmbH Neue selektionsverfahren
US20040149174A1 (en) * 2003-02-05 2004-08-05 Mbt Holding Ag Accelerating admixture for concrete
CA2531773A1 (en) 2003-07-21 2005-02-17 Transgene S.A. Novel multifunctional cytokines
PT1649023E (pt) 2003-07-21 2008-11-20 Transgene Sa Polipéptido com actividade de citosina desaminase melhorada
EP1687032B1 (de) * 2003-11-14 2010-02-24 Genvec, Inc. Pharmazeutische verbindung zur behandlung von lokal fortgeschrittenem primär inoperablen pankreaskarzinom (lapc).
CA2558372C (en) * 2004-03-17 2017-01-17 Basf Plant Science Gmbh Improved constructs for marker excision based on dual-function selection marker
EP1727907A1 (de) * 2004-03-17 2006-12-06 BASF Plant Science GmbH Kontrolle des wachstums gentechnisch veränderter kulturpflanzen nach der ernte unter einsatz von d-aminosäureverbindungen
DE602005025340D1 (de) 2004-05-26 2011-01-27 Bayer Schering Pharma Ag Chimäre adenoviren zur verwendung in der krebsbehandlung
CN101001951B (zh) 2004-08-02 2011-06-15 巴斯福植物科学有限公司 分离转录终止序列的方法
US8034994B2 (en) 2005-04-19 2011-10-11 Basf Plant Science Gmbh Starchy-endosperm and/or germinating embryo-specific expression in mono-cotyledonous plants
US20070026012A1 (en) 2005-08-01 2007-02-01 Cornell Research Foundation, Inc. Compositions and methods for monitoring and altering protein folding and solubility
CA2620934C (en) 2005-08-22 2014-07-22 Cornell Research Foundation, Inc. Compositions and methods for determining protein interactions using tat signal sequence and marker protein
CA2675926A1 (en) 2007-02-16 2008-08-21 Basf Plant Science Gmbh Nucleic acid sequences for regulation of embryo-specific expression in monocotyledonous plants
US20090196854A1 (en) * 2008-02-04 2009-08-06 Kytos Biosystems S.A. Methods and compositions for use of crl 5803 cells for expression of biotherapeutics and encapsulated cell-based delivery
AU2009303690B2 (en) 2008-09-26 2014-06-19 Tocagen Inc. Gene therapy vectors and cytosine deaminases
EP2248903A1 (de) 2009-04-29 2010-11-10 Universitat Autònoma De Barcelona Verfahren und Reagenzien zum effizienten und gezielten Gentransfer in Monozyten und Makrophagen
US9605844B2 (en) * 2009-09-01 2017-03-28 Cree, Inc. Lighting device with heat dissipation elements
ES2696173T3 (es) * 2011-12-21 2019-01-14 Cj Cheiljedang Corp Método para producir L-lisina usando microorganismos que tienen capacidad de producir L-lisina
EP2877572B1 (de) 2012-07-24 2018-11-28 The General Hospital Corporation Onkolytische virustherapie für resistente tumoren
TR201802728T4 (tr) 2013-10-25 2018-03-21 Psioxus Therapeutics Ltd Heterolog genlerle donatılmış onkolitik adenovirüsler.
US20160303174A1 (en) 2013-12-11 2016-10-20 The General Hospital Corporation Stem cell delivered oncolytic herpes simplex virus and methods for treating brain tumors
DK3129037T3 (da) 2014-04-10 2020-02-03 Transgene Onkolytiske koppevirusvektorer
US20180112006A1 (en) 2015-04-17 2018-04-26 The General Hospital Corporation Agents, systems and methods for treating cancer
WO2016174200A1 (en) 2015-04-30 2016-11-03 Psioxus Therapeutics Limited Oncolytic adenovirus encoding a b7 protein
BR112018012180A2 (pt) 2015-12-17 2018-12-04 Psioxus Therapeutics Ltd vírus de codificação de um anticorpo ou fragmento de complexo anti-tcr
GB201713765D0 (en) 2017-08-28 2017-10-11 Psioxus Therapeutics Ltd Modified adenovirus
KR102371151B1 (ko) 2020-03-13 2022-03-07 주식회사 큐로셀 항-bcma 결합 영역, 이를 포함하는 융합단백질, 및 이를 포함하는 조성물

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4975278A (en) * 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
CA2018273C (en) * 1989-06-09 1999-04-06 Peter D. Senter Thermally stable cytosine deaminase
GB8919607D0 (en) * 1989-08-30 1989-10-11 Wellcome Found Novel entities for cancer therapy
US5358866A (en) * 1991-07-03 1994-10-25 The United States Of America As Represented By The Department Of Health And Human Services Cytosine deaminase negative selection system for gene transfer techniques and therapies

Also Published As

Publication number Publication date
EP0595873B1 (de) 2000-04-05
JPH07501925A (ja) 1995-03-02
AU667820B2 (en) 1996-04-18
CA2112395A1 (en) 1993-01-21
AU2295992A (en) 1993-02-11
GR3033909T3 (en) 2000-11-30
DE69230882D1 (de) 2000-05-11
CA2112395C (en) 2008-04-22
US5358866A (en) 1994-10-25
JP3386461B2 (ja) 2003-03-17
US5624830A (en) 1997-04-29
WO1993001281A1 (en) 1993-01-21
DK0595873T3 (da) 2000-07-10
ES2152929T3 (es) 2001-02-16
SG52475A1 (en) 1998-09-28
EP0595873A4 (de) 1994-12-07
ATE191505T1 (de) 2000-04-15
EP0595873A1 (de) 1994-05-11

Similar Documents

Publication Publication Date Title
DE69230882T2 (de) Cytosindeaminase negatives selektionssystem zur genübertragung und therapien
DK0500917T3 (da) Vacciner og fremgangsmåder baseret på rekombinante herpes simplex virusser.
ES2121794T3 (es) Procedimiento de transferencia de genes por medio de retrotransposones.
AU7945682A (en) Rennin from recombinant dna
AU6857696A (en) Methods for enhancing the production of interferon in cell culture
DE60303810D1 (de) Kontrollierte bakterielle lyse zur verabreichung von dna vakzinvektoren und impfantigen
ATE270342T1 (de) Endosomolytisch wirksame partikel
ES8705036A1 (es) Procedimiento para preparar una vacuna que comprende un polipeptido fijado a una membrana
MXPA03000634A (es) Metodos para el reemplazo, el desplazamiento y acumulacion de adn en genomas eucarioticos.
HK1018078A1 (en) Recombinant sendai virus
EP0732397A3 (de) Modifizierte Hepatozyten und deren Verwendungen
DK0617736T3 (da) Anvendelse af Bacillus thuringiensis isolater til bekæmpelse af skadedyr i familien Aphididae
DE69734829D1 (de) Infektiöse pseudovirale papillomavirus partikel
DE69033961T2 (de) Zellinien, die einen biologisch aktiven faktor-ix exprimieren
DE69736838D1 (de) Herpesvirus saimiri als viraler vektor
Doersen et al. Cytoplasmic inheritance of erythromycin resistance in human cells.
HUP0401585A2 (hu) Fertőző, marhában előforduló, vírusos hasmenés vírusklónja
DE60016429D1 (de) Zell- und/oder tumor-spezifische promotor-abhängige änderung der gezielten expression des herpes gamma 34.5 gens
EP0914422A4 (de) Säugetiergene, die an viraler infektion und tumorunterdrückung beteiligt sind
AU2190288A (en) Vector for the expression of proteins of the HIV-2 virus, one of the casual agents of AIDS, cell culture infected or transformed by this vector, proteins obtained, vaccine and antibodies obtained
AU6262786A (en) Growing aids virus in cell lines lacking human class ii histocompatability antigens
Mullen et al. Cytosine deaminase negative selection system for gene transfer techniques and therapies
DK204586A (da) Hybridceller, der producerer et karakteristisk antigen for hepatitis b-virus, opnaaet ud fra hepatocytter og celler, der er tilvejebragt fra aber, fremgangsmaade til opnaaelse af hybridcellerne og anvendelse af disse til produktion af antigenet

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee